ACL is starting to look seriously under valued when compared to other in the sector. ACR now capped at M$235 and has only just past phase three test for testosterone. Their other product isn't exactly setting the world on fire. It sure makes ACL look very undervalued from where they are now sitting. If their had been problems with FDA ACL would have been getting queries by now. Lets hope ACL gets rerated to a much higher level soon. PoS
seriously undervalued.
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable